Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Grace Kong's publication output changed over time?
ScholarIQpublication output · 2006–2023
Output grew0% over the shown period — from 1 works in 2006 to 1 in 2023.
1
1
1
1
3
2
1
1
20062012201620172018201920222023
What are the most-cited papers on Grace Kong?
ScholarIQmost cited works
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
Michael S. Hofman, John Violet, Rodney J. Hicks, Justin Ferdinandus, Sue Ping Thang, Tim Akhurst, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Declan G. Murphy, Peter Eu, Price Jackson, Mark Scalzo, Scott Williams, Shahneen Sandhu
The Lancet Oncology. 20181,163 Citations
Dosimetry of <sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes
John Violet, Price Jackson, Justin Ferdinandus, Shahneen Sandhu, Tim Akhurst, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Sue Ping Thang, Peter Eu, Mark Scalzo, Declan G. Murphy, Scott Williams, Rodney J. Hicks, Michael S. Hofman
S4210180780. 2018502 CitationsOPEN ACCESS
Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of <sup>177</sup>Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer
John Violet, Shahneen Sandhu, Amir Iravani, Justin Ferdinandus, Sue-Ping Thang, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, David A. Pattison, Alexis Beaulieu, Jennifer Mooi, Ben Tran, Christina Guo, Victor Kalff, Declan G. Murphy, Price Jackson, Peter Eu, Mark Scalzo, Scott Williams, Rodney J. Hicks, Michael S. Hofman
S4210180780. 2019287 CitationsOPEN ACCESS
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
James P Buteau, Andrew Martin, Louise Emmett, Amir Iravani, Shahneen Sandhu, Anthony M. Joshua, Roslyn J. Francis, Alison Y. Zhang, Andrew M. Scott, Sze-Ting Lee, Arun Azad, Margaret McJannett, Martin R. Stockler, Scott Williams, Ian D. Davis, Michael S. Hofman, Michael S Hofman, Tim Akhurst, Ramin Alipour, Arun A Azad, Patricia Banks, Alexis Beaulieu, James P Buteau, Wei Chua, Ian D Davis, Nattakorn Dhiantravan, Louise Emmett, Kate Ford, Michael S Hofman, Michael S Hofman, Roslyn J Francis, Craig Gedye, Jeffrey C. Goh, Alex Guminski, Anis Hamid, Mohammad B. Haskali, Rodney J. Hicks, Edward Hsiao, Amir Iravani, Anthony M Joshua, Ian Kirkwood, Grace Kong, Edmond M. Kwan, Ailsa Langford, Nicola Jane Lawrence, Sze-Ting Lee, Jeremy Lewin, Peter Lin, Andrew J Martin, William M. McDonald, Margaret M McJannett, Kate Moodie, Declan G. Murphy, Siobhan Ng, David A. Pattison, Izabella Pokorski, Shakher Ramdave, Aravind S. Ravi Kumar, Andrew Redfern, Natalie Rutherford, Javad Saghebi, Shahneen Sandhu, Andrew M Scott, Lavinia Spain, Martin R Stockler, Shalini Subramaniam, Thean Hsiang Tan, Sue Ping Thang, Ben Tran, Roslyn E. Wallace, Andrew Weickhardt, Scott G Williams, Sonia Yip, Alison Y. Zhang
The Lancet Oncology. 2022277 Citations
High management impact of Ga‐68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours
Michael S. Hofman, Grace Kong, Oliver Neels, Peter Eu, Emily Hong, Rodney J. Hicks
S202179756. 2012252 CitationsOPEN ACCESS
Related on ScholarIQ
The University of Melbourne
Institution
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
Paper
Dosimetry of <sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes
Paper
Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of <sup>177</sup>Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer
Paper
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
Paper
High management impact of Ga‐68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours
Paper